59 results about "Release factor" patented technology

This invention relates to growth hormone releasing factor (GRF) derivatives. In particular, this invention relates to GRF peptide derivatives having an extended in vivo half-life, for promoting the endogenous production or release of growth hormone in humans and animals.

The invention discloses an automatic sleep staging method of a single-lead electroencephalogram. A training model comprises a feature extraction module and a staging optimization module, the feature extraction module comprises CNNs (convolutional neural networks) (1) and an Softmax layer (2), the staging optimization module comprises bi-directional LSTM (long-short term memory) recurrent neural networks (3) and a CRF (corticotropin releasing factor) conditional random field model (4), and the CNNs (1), the Softmax layer (2), the LSTM recurrent neural networks (3) and the CRF conditional random field model (4) are sequentially connected. The method only needs the single-lead sleep electroencephalogram, portable and comfortable sleep monitoring requirements are met, temporal and spatial characteristics of the electroencephalogram are sufficiently excavated according to the convolutional neural networks and the recurrent neural networks, the method has dynamic learning capacity and can adapt to great changed environments of diseases, the staging optimization module sufficiently considers relation between the front and the back of N 30s of electroencephalogram data, and the staging accuracy and the generalization ability of the model are improved.

The invention relates to genomically recoded organisms, platforms for preparing sequence defined biopolymers in vitro comprising a cellular extract from a genomically recorded organism, and methods for preparing sequence defined biopolymers in vitro are described. In particular, the invention relates to genomically recoded organisms comprising a strain deficient in release factor 1 (RF-1) or a genetic homolog thereof and at least one of at least one additional genetic knock-out mutation, at least one additional upregulated gene product, or both at least one additional knock-out mutation and at least one additional upregulated gene product.

Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.

The present invention relates to process of extracting growth hormone release factor (GHRF) from pilose antler. The process includes the following steps: 1. crushing pilose antler and leaching to obtain leached liquid; 2. ultrafiltering the leached liquid and collecting the pilose antler extract of molecular weight 1-10 kDa; and 3. high efficiency liquid chromatography on the pilose antler extract and collecting component containing GHRF of pilose antler. The present invention also relates to the pilose antler extract with rich GHRF, and its application in medicine, food, cosmetics, feed, etc.

The invention belongs to the technical field of medicine compositions, and discloses an external use medicine composition used for treating alopecia. The external use medicine composition comprises annular adrenocorticotrophic hormone release factor (CRF) antagonism peptide astressin B in effective treatment amount or acceptable salt on the pharmacy. The external use medicine composition is in a gel dosage form preferably and suitable for clinic use and industrialization production. In addition, the invention further discloses a method for preparing the external use medicine composition and application of the astressin B in effective treatment amount or the acceptable salt on the pharmacy to preparing the external use medicine composition used for treating the alopecia. According to the external use medicine composition, the problem of the alopecia for a long time can be effectively treated; and the external use medicine composition is safe, reliable, free of obvious skin irritants and free of sensitization.

In some aspects, the invention relates to methods for increasing insulin-sensitivity and/or decreasing insulin secretion in an individual by reducing or inhibiting corticotropin releasing factor 2 (CRFR2) signaling. CRFR2 antagonists may block agonism by one or more CRFR2 agonist, for example Ucn 2 or Ucn 3. Methods according to the invention may be use to treat a variety of metabolic diseases such as type 2 diabetes, metabolic syndrome, nonalcoholic fatty liver disease, polycystic ovarian syndrome and obesity.

The invention provides a series of fusion proteins comprising human luteinizing hormone releasing factor (GnRH) or its mutant and pseudomonas exotoxin (PE) or its mutant. The medicinal purpose of the GnRH is for the highly effective eradication of tumor cells.

The present invention provides transgenic mice deficient in corticotropin releasing factor receptor 2 (CRFR2). Mice deficient for CRFR1 exhibit decreased anxiety-like behavior and a decreased stress response. In contrast, CRFR2 null mutant mice are hypersensitive to stress and display increased anxiety-like behavior. These mice are useful for the study of anxiety, depression, and the physiology of the HPA axis. CRFR2 null mutant mice also exhibit increased angiogenesis in all tissues examined. Thus, CRFR2 antagonists may be used to stimulate angiogenesis for the treatment of various conditions. In contrast, CRFR2 agonists may be used to inhibit angiogenesis. A combination of urocortin and bFGF was observed to stimulate rapid hair growth.

Analysis of a goat serum product with many therapeutic effects is described. The product is identified as containing proopiomelanocortin (POMC) and Corticotropin releasing factor (CRF) peptides, as well as breakdown products of these peptides. We describe methods of treatment of diseases including cancers, multiple sclerosis, and neural disorders using these peptides and their products, as well as medicaments including such peptides and methods of producing the peptides.

The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I) pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.

A method for treating or preventing a host mammal that exhibits aversive signs and symptoms present during protracted abstinence or extended discontinuation syndromes as seen after cessation of compulsive activity, behaviors, or substance use is disclosed. That method comprises administering to a host mammal in need a pharmaceutical composition containing an aversive sign and symptom lessening amount a compound of Formula I or a pharmaceutically acceptable salt thereof dissolved or dispersed in a physiologically acceptable diluent, and repeating the administration as needed,

wherein W, X, Y and Z, R¹ and Ar are defined within. Data are provided in rats as host mammals using behavioral models dependent on the CRF₁ system: defensive burying, alcohol dependence, cocaine dependence and nicotine dependence. A contemplated method also is useful for inhibiting relapse of such a behavior. A contemplated method also is useful for treating substance-related or substance-induced psychiatric disorders that include aversive signs and symptoms.

Screening methods for identifying compounds that bind to or activate corticotropin releasing factor₂ receptors (CRF₂R) and regulate or potentially regulate skeletal muscle mass or function in vivo are disclosed. Also disclosed are screening methods for identifying compounds that prolong or augment the activation of CRF₂Rs or of CRF₂R signal transduction pathways, increase CRF₂R or increase CRF expression are provided. Pharmaceutical compositions comprising CRF₂R agonists, antibodies to CRF₂R and methods for increasing skeletal muscle mass or function or for the treatment of skeletal muscle atrophy using CRF₂R as the target for intervention and methods for treatment of muscular dystrophies are described.

The invention relates to a method for expressing recombinant protein containing unnatural amino acid in animal cells, which comprises the following steps: on the basis of four groups of aminoacyl-tRNA synthetases and corresponding tRNA, constructing aminoacyl-tRNA for identifying termination codons, and screening to obtain three gene codon expansion systems. The three gene codon expansion systems are high in termination codon reading efficiency and high in mutual compatibility, so that three non-natural amino acids can be inserted into one foreign protein, or different non-natural amino acids can be inserted into three foreign proteins of the same cell respectively. In order to further improve the readthrough rate, the release factor eRF1 is mutated to weaken the interaction between the release factor eRF1 and the termination codon.